section name header

Pronunciation

glye-ME-pye-ride

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sulfonylureas

Indications

BEERS REMS, High Alert


Action

  • Lowers blood sugar by stimulating the release of insulin from the pancreas and increasing the sensitivity to insulin at receptor sites.
  • May also decrease hepatic glucose production.
  • May be used concurrently with metformin when the combination of diet, exercise, and either drug alone fails to produce glycemic control.
Therapeutic effects:
  • Lowering of blood sugar in diabetic patients.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 99.5%.

Metabolism/Excretion: Mostly metabolized by the liver; one metabolite has hypoglycemic activity.

Half-Life: 5–9.2 hr.

Time/Action Profile

(hypoglycemic activity)

ROUTEONSETPEAKDURATION
POunknown2–3 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: photosensitivity, rash

Endo: hypoglycemia

F and E: hyponatremia

GI: constipation, cramps , diarrhea, dyspepsia, hepatitis, nausea, vomiting

Hemat: hemolytic anemia, thrombocytopenia

Metab: appetite

Neuro: dizziness, drowsiness, headache, weakness

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Amaryl